R&D channel feed

Macro­Gen­ics, Ab­b­Vie stop de­vel­op­ment of part­nered ADC

Last year
Deals

Amy­lyx's ALS treat­ment Re­lyvrio fails PhI­II study, biotech to con­sid­er with­draw­ing drug

Last year

Kro­nos Bio cuts a fifth of staff, ex­plores new dos­ing sched­ule for sol­id tu­mor drug

Last year
People

David Bak­er's lab re­leas­es new pro­tein de­sign and study tools as AI race ac­cel­er­ates

Last year
AI
Discovery

Bris­tol My­ers nabs ap­proval for Op­di­vo com­bo as first-line blad­der can­cer treat­ment

Last year
Pharma
FDA+

Up­dat­ed: Even with no pri­ma­ry end­point da­ta, Tau­Rx still eyes Alzheimer’s fil­ing af­ter PhI­II up­date

Last year

No­vo touts ear­ly da­ta for next-gen oral weight loss drug as it out­lines next steps

Last year
Pharma

Mer­ck KGaA to fo­cus on ‘ex­ter­nal in­no­va­tion’ as it ex­its BTK in­hibitor race

Last year
Deals

GSK de­clares sec­ond PhI­II win for Blenrep com­bo in bid to re­vive drug

Last year

Third anti­gen's a charm: Gilead pens deal with Merus for up to three trispe­cif­ic an­ti­bod­ies 

Last year
Deals

Alu­mis clos­es a $259M Se­ries C to back its TYK2, flirts with talk about an IPO

Last year
Financing

Re­genxbio gives glimpse at ear­ly Duchenne gene ther­a­py re­sults, plans piv­otal study for ac­cel­er­at­ed ap­proval

Last year
Cell/Gene Tx

Roche, Al­ny­lam’s zilebe­sir­an suc­ceeds in an­oth­er PhII hy­per­ten­sion test

Last year

Amy­lyx read­ies for make-or-break PhI­II, look­ing to ad­dress un­cer­tain­ty over con­tro­ver­sial ALS drug

Last year
Pharma
In Focus

Bay­er on job cuts, pipeline gaps, obe­si­ty and Mon­san­to lit­i­ga­tion as ex­ecs de­fend keep­ing cur­rent struc­ture

Last year
Pharma

No­vo’s kid­ney dis­ease win for Ozem­pic adds to case for ex­pand­ed use in di­a­bet­ic pa­tients

Last year

Swedish biotech un­veils topline da­ta on weight loss drug de­signed for main­te­nance af­ter GLP-1s

Last year

Cor­rect­ed: Mer­ck KGaA bags an­oth­er pro­tein de­grad­er deal for $16M up­front, this time with C4

Last year
Deals

Akero re­turns with more MASH da­ta to back PhI­II drug, touts fi­bro­sis re­sponse rate

Last year

J&J's Janssen nabs new in­di­ca­tion, full ap­proval for can­cer drug Ry­bre­vant

Last year
FDA+

Pfiz­er lays out am­bi­tious vi­sion for can­cer port­fo­lio in bid to rein­vig­o­rate its busi­ness

Last year

GAO di­rects ARPA-H to fi­nal­ize plan for han­dling du­pli­cate re­search

Last year
Pharma
FDA+

Cardiff teas­es on­va­nsert­ib ef­fi­ca­cy in col­orec­tal can­cer ahead of first-line read­out

Last year

Grit­stone bio lays off 40% of staff fol­low­ing Covid vac­cine tri­al de­lay

Last year
People
First page Previous page 52535455565758 Next page Last page
A service from the Financial Times